ELV's unique strength is its exclusive license to the Blue Cross Blue Shield brand in 14 states, providing a 'moat' of brand recognition that competitors struggle to match in those territories. The company has successfully built the infrastructure of a modern health giant through Carelon, but it is currently being buffeted by a 'perfect storm' of rising medical costs and shrinking government reimbursements.
Cyborg Score Rationale
The company faces significant headwinds from the 'One Big Beautiful Bill Act' mandating Medicaid cuts, while the Trump administration's focus on flat Medicare Advantage rates pressures the entire sector. However, strong Carelon growth and market position provide resilience amid transformation.
Top Insights
FY 2025 Revenue: $197.6 billion, up 13% year-over-year.
Carelon's revenue climbed 27% to $18.7 billion, demonstrating strong growth in the high-margin services segment.
Medicaid operating margins expected at approximately negative 1.75% for 2026, reflecting the core profitability challenge.
CEO Gail Boudreaux said Elevance anticipates returning to at least 12% adjusted EPS growth in 2027, signaling management confidence in recovery trajectory.
Named Competitors
Medicare Advantage — Largest managed-care competitor with extensive MA portfolio
Humana Plans — Major competitor in Medicare Advantage and Medicaid
Aetna Plans — Integrated healthcare and PBM competitor
Anthem Plans — Core health insurance brand and market leader
Recent Developments
(January 2026) Elevance reported Q4 2025 results with $49.3B quarterly revenue and issued cautious 2026 guidance amid regulatory uncertainty.
(January 2026) Stock experienced significant volatility following Medicare Advantage rate announcement (0.09% increase for 2027).
(April 2025) Acquisition of Granular Insurance Company to expand service capabilities.
Open the full interactive Elevance Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.